TP53 and breast carcinoma: To empirically test this hypothesis, we conducted a proof-of-concept analysis on two distinct human microcohorts, one in breast cancer (BC) (TP53 vs PIK3CA tumors) and one in human rhinovirus (HRV) infection (symptomatic vs asymptomatic), each comprising paired biological samples representing two different tissue conditions per subject.